KAO JOHN E 4

What Happened
John E. Kao, CEO of Alignment Healthcare, sold a total of 250,000 shares in two open‑market transactions on April 7, 2026, generating approximately $5,252,910 in proceeds. The sales were reported as: 132,241 shares at a weighted‑average price of $20.67 (proceeds $2,733,421) and 117,759 shares at a weighted‑average price of $21.40 (proceeds $2,519,489). These were sales (S), not purchases.

Key Details

• Transaction date: April 7, 2026; Form 4 filed April 8, 2026 (timely filing).
• Prices: reported as weighted averages: $20.67 (132,241 sh) and $21.40 (117,759 sh). Individual trade prices ranged from $20.18–$21.17 and $21.18–$21.56 per footnotes.
• Total shares sold: 250,000; total proceeds: ~$5.25 million.
• Footnote: Sales executed pursuant to a Rule 10b5‑1 trading plan adopted 11/21/2025. Reporting person offered to provide breakdown of shares sold at each price within the ranges.
• Footnote: Some reported securities are held by the JEK Trust (dated Feb 8, 2021), of which Mr. Kao is trustee.
• Shares owned after the transactions: not disclosed in the provided excerpt of the filing.

Context

• Sales under a 10b5‑1 plan are pre‑scheduled transactions and are generally viewed as routine insider selling rather than a real‑time signal of sentiment.
• These were open‑market sales (not option exercises, gifts, or awards), so proceeds were received by the seller.
• Retail investors should treat this as insider liquidity activity; purchases usually carry more weight for interpreting insider confidence.